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Introduction
Systemic lupus erythematosus (SLE) is considered a 
prototypic autoimmune disease, although it cannot be 
ruled out that SLE is actually a syndrome representing 
the common ﬁ   nal pathway of a number of discrete 
genetic and molecular aberrations. Th   e large numbers of 
genetic abnormalities that can induce a lupus-like syn-
drome in mice [1] are consistent with the possibility that 
SLE may be a syndrome reﬂ   ective of a number of 
diﬀ  erent molecular abnormalities. Most of these murine 
models of lupus, however, are associated with diﬀ  use 
B-cell hyperactivity or defects in the clearance of 
apoptotic material or both. Th   e available data from these 
models, therefore, suggest that abnormalities of B-cell 
activation or clearance of apoptotic material of a variety 
of sorts (or both) may be the deﬁ  ning molecular pathways 
in human SLE.
Both mice and human subjects with SLE produce a 
number of autoantibodies against nuclear complexes, 
although the proﬁ  le of these antibodies can vary widely 
between individual subjects and murine models. Central 
to both human lupus and the various animal models is 
the production of antibodies to DNA and other compo-
nents of the nucleosome. Traditionally, serologic evalua-
tion has been used to delineate immunologic abnormali-
ties in SLE, but it has also been known for many years 
that both mice and humans with SLE typically show 
evidence of polyclonal B-cell hyper-reactivity. More 
recently, analyses largely employing ﬂ  ow  cytometry 
have documented the speciﬁ  c perturbations of B-cell 
matura  tion and diﬀ   erentiation in lupus and have 
generated new information on whether alterations in 
B-cell diﬀ   erentia  tion are involved primarily in 
immunopathology or, alternatively, may be secondary to 
the inﬂ   ammatory environment in SLE (Figure 1). 
Additional insights have been derived from an analysis 
of the impact of certain therapies on clinical disease 
activity as well as their eﬀ  ects on abnormalities of B-cell 
subsets in SLE. All of these new data on human lupus, 
informed by advances in the study of murine lupus, 
have enhanced our under  standing of the pathogenic 
role of B cells in SLE and also provided new information 
on the identiﬁ  cation of potential therapeutic targets in 
this autoimmune disease. Moreover, an emerging 
understanding of the central role of B  cells in lupus 
pathogenesis has provided the oppor  tunity to monitor 
speciﬁ  c B-cell subsets as biomarkers of disease activity 
and clinical response to therapy.
Abstract
Systemic lupus erythematosus (SLE) is a systemic 
autoimmune disease that is known to be associated 
with polyclonal B-cell hyper-reactivity. The underlying 
causes of the diff  use B-cell over-reactivity are unclear, 
but potential candidates include (a) intrinsic hyper-
reactivity leading to polyclonal B-cell activation 
with disturbed activation thresholds and ineff  ective 
negative selection; (b) lack of immunoregulatory 
functions; (c) secondary eff  ects of an overactive 
infl  ammatory environment, such as overactive 
germinal center and ectopic follicular activity; and/or 
(d) disturbed cytokine production by non-B immune 
cells. These mechanisms are not mutually exclusive 
and may operate to varying extents and at varying 
times in SLE. Phenotypic and molecular studies as 
well as the results of recent clinical trials have begun 
to provide new insights to address these possibilities. 
Of importance, new information has made it possible 
to distinguish between the contribution played by 
abnormalities in central checkpoints that could lead 
to a pre-immune repertoire enriched in autoreactive 
B cells, on the one hand, and the possibility that 
autoimmunity arises in the periphery from somatic 
hypermutation and abnormal selection during T cell-
dependent B-cell responses on the other. There is an 
intriguing possibility that apoptotic material bound to 
the surface of follicular dendritic cells positively selects 
autoreactive B cells that arise from non-autoreactive 
B-cell precursors as a result of somatic hypermutation 
and thereby promotes the peripheral emergence of 
autoimmunity.
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autoimmune diseases
Increased knowledge of the roles of B  cells in normal 
immune responses, in particular their capacity to diﬀ  er-
entiate into antibody-secreting plasmablasts and plasma 
cells as well as their ability to function as antigen-
presenting cells (APCs), secrete cytokines, and inﬂ  uence 
lymphoid architecture, has focused attention on them as 
a therapeutic target in autoimmune disease. In addition, 
genome-wide association studies have identiﬁ  ed a number 
of candidate genes, such as BANK1, BLK, IL-21R, CD40, 
Lyn,  PTPN22, TNFAIP3, FcγRs, and Blimp-1, that are 
associated with SLE and other autoimmune diseases and 
could predispose to increased B-cell responsiveness [2-4]. 
Finally, studies in genetically manipulated mice have 
indicated that a variety of interventions that serve to 
increase B-cell res  ponsive  ness can lead to the production 
of autoantibodies and, in the appropriate genetic strain, a 
lupus-like syndrome [1]. Recently, it has also been shown 
that disruption of genes with wide expression can result 
in B-cell hyper-responsiveness. In this regard, mice 
lacking the A20 molecule that restricts nuclear factor-
kappa-B (NF-κB) activation by tumor necrosis factor 
(TNF) receptor family members and is encoded by the 
tnfaip3 gene, polymorphisms of which have been 
associated with SLE, develop exaggerated B-cell activity, 
increased germinal center (GC) activity, autoantibodies, 
and glomerular deposits of immunoglobulin (Ig) [5]. 
Together, these ﬁ   nd  ing have caused the targeting of 
B cells to be considered potential interventions in various 
autoimmune diseases.
Initially, B  cell-depleting therapy was employed in 
rheumatoid arthritis because of the belief that it would 
diminish rheumatoid factor production and thereby 
ameliorate disease activity [6] and even induce remission. 
Although the actual mechanism whereby B cell-depleting 
therapy is eﬀ   ective in rheumatoid arthritis remains in-
completely delineated, rituximab has been approved and 
adopted for treatment of this autoimmune/inﬂ  ammatory 
disease. Subsequently, trials have been carried out in SLE, 
ANCA+ (anti-neutrophil cytoplasmic antibody-positive) 
vasculitis, Sjögren’s syndrome, immune thrombocyto-
penia, multiple sclerosis, autoimmune myositis, and other 
auto  immune conditions [7]. Although trials of rituximab 
in SLE [8] did not achieve their primary clinical endpoints, 
lymphocyte monitoring after B  cell-targeted therapy [9] 
was instrumental in documenting the biologic impact of 
the intervention and also characteristics of the B-cell 
repopulation which are associated with clinical response. 
More recently, a monoclonal antibody to the B-cell 
survival factor BAFF/BLyS (B  cell-activating factor/B 
lymphocyte stimulator) (TNFSF13b) was shown to be 
eﬀ   ective in clinical trials of non-renal lupus and was 
approved in the US and Europe in 2011.
Figure 1. Scheme of potential aberrations of T cell-dependent activation of B cells under the conditions of systemic lupus erythematosus. 
Intrinsic as well as extrinsic factors may lead to known B-cell hyperactivity as a result of enhanced germinal center reactions with defects in 
selection. As a net result, enhanced memory B cells and plasmacytosis could be explained and are consistent with abnormalities detectable in the 
blood of patients with active systemic lupus erythematosus.
Dörner et al. Arthritis Research & Therapy 2011, 13:243 
http://arthritis-research.com/content/13/5/243
Page 2 of 12B-cell subsets in human systemic lupus 
erythematosus
Th   e abnormalities of certain peripheral B-cell subsets in 
SLE compared with healthy subjects were reviewed 
recently [10]. Diﬀ  erences from healthy subjects suggest 
that mechanisms that control many aspects of B-cell 
biology, including pre-immune B-cell maturation, 
negative selection at deﬁ  ned maturational checkpoints, 
and receptor editing, as well as many aspects of antigen 
responsiveness, including somatic hypermutation and 
eﬀ   ector B-cell generation, are diﬀ   usely abnormal in 
subjects with SLE. Whether this reﬂ   ects an intrinsic 
B-cell defect or is secondary to inﬂ  ammation is unclear. 
Reﬂ  ecting abnormalities in B-cell maturation, a number 
of alterations in pre-immune B-cell populations in the 
periphery have been noted in patients with SLE. In the 
peripheral blood, abnormal frequencies of pre-immune 
B cells, including transitional B cells, pre-naïve B cells, 
and naïve B cells, can be detected [11]. Th  ese  populations 
denote major stages of B-cell maturation which occur 
outside the bone marrow. In SLE, both transitional B cells 
and pre-naïve B  cells are greatly expanded. Th  ese 
populations can be deﬁ   ned by a variety of markers, 
including CD38, CD5, CD9, CD10, CD24, and the 
ABCB1 transporter [11]. Th  ese results indicate a popu-
lation shift within the pre-immune B-cell compartment 
in SLE toward the more immature B cells, and this shift is 
independent of disease activity.
With regard to early defects of selection against auto-
reactive B cells, a comprehensive study [12] showed that 
even patients with inactive SLE fail to remove B  cells 
expressing self-reactive B-cell receptors (BCRs) expressed 
by naïve B  cells. Consistent with this, earlier studies 
demon  strated that self-reactivity or loss of proper selec-
tion during early B-cell development from immature 
(CD10+CD27−IgM+ B cells) to mature (CD10−CD27−IgM+ 
B cells) naïve B cells is a feature in SLE [13]. Although it is 
tempting to conclude that SLE has defects in ‘checkpoints 
against autoimmunity’ that explain the development of 
pathogenic IgG autoantibodies, the possibility cannot be 
excluded that these ‘checkpoints’ are active in SLE to 
prevent serious autoimmunity but are simply over  whelmed 
by chronic polyclonal B-cell activation. Alterna  tively, it is 
possible that, since some predominantly IgM auto-
antibodies may be protective, defects in selection at pre-
immune check  points represent an eﬀ  ort to enhance the 
production of non-pathogenic protective autoantibodies.
Disturbances of memory B cells in systemic lupus 
erythematosus
A central ﬁ  nding in phenotyping peripheral blood B cells 
in adult SLE is the substantial increase of antigen-
experienced CD27+IgD− post-switched memory B  cells 
[14], which are less susceptible to immunosuppressive 
therapy [10,14]. Importantly, the peripheral memory 
BCR repertoire in SLE is shaped by abnormal selection, 
exaggerated somatic hypermutation, and increased recep-
tor editing [15,16]. In contrast, the pre-immune BCR 
initially generated by VH(D)JH recombination appears 
similar to that of  healthy subjects [17]. Moreover, 
autologous stem cell transplantation in SLE provides 
proof of con  cept that the disease can undergo successful 
remission along with the emergence of predominating 
naïve T and B  cells after transplantation [18]. Th  is is 
consistent with the conclusion that abnor  malities in the 
shaping of the Ig repertoire after antigenic stimulation 
and diﬀ   erentiation of memory B  cells, rather than 
molecular disturbances in generating the initial BCR 
repertoire of pre-immune B cells, may be more important 
in lupus pathogenesis.
It is currently unclear whether the predominance of 
IgD−CD27+ post-switched memory B cells reﬂ  ects a loss 
of peripheral tolerance or abnormal selection processes 
or whether their appearance is simply the result of 
enhanced activation and diﬀ  erentiation of naïve B cells or 
the lack of susceptibility of memory B cells to immuno-
suppressive drugs. Independently of these considerations, 
an enlarged pool of memory B cells poses a risk for auto-
immunity since these cells have lower activation 
thresholds, regulation by FcγRIIb receptors may be 
reduced [19], and these cells can be rapidly activated in a 
non-antigen-speciﬁ  c manner by the combination of Toll-
like receptor (TLR) agonists and a proliferation-inducing 
ligand (APRIL) (TNFSF13A) or BAFF (TNFSF13B) as 
well as by the combi  nation of cytokines, such as IL-21 
and BAFF [20].
Another memory B-cell subset particularly enhanced 
in patients with SLE, besides the large subset of 
IgD−CD27+ post-switched cells, has also been identiﬁ  ed. 
Th  is is a population of memory B  cells that does not 
express CD27 [21-23]. CD27− B  cells were previously 
thought to be exclusively naïve B cells and to express IgD 
[23], but in SLE an expanded population of IgD−CD27− 
B cells with characteristics of memory B cells could be 
detected. While in normal donors IgG+CD27− B  cells 
expressing mutated BCRs have been identiﬁ  ed both in 
tonsils and in very small numbers in peripheral blood 
[24,25], CD27−IgD− memory B  cells in the peripheral 
blood were increased in patients with SLE and that 
increase has been reported to be associated with 
increased disease activity and active renal disease [22]. 
Th  e frequency of these IgD−CD27− memory B cells was 
also reported to correlate with the presence of certain 
autoantibodies – anti-dsDNA (anti-double-stranded 
DNA), anti-Smith, and anti-ribonucleoprotein – and the 
presence of B cells expressing the 9G4 idiotype expressed 
by the VH4-34 heavy chain [22] and frequently encoding 
anti-DNA autoantibodies [26]. Similar to transitional 
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B cells, these CD27−IgD− B cells lack expression of the 
ABCB1 transporter and are, therefore, unable to extrude 
the ﬂ  uorescent dye, rhodamine123.
Subsequently, a more homogeneous subset of 
IgD−CD27−CD95+ memory B cells was found among the 
IgD−CD27− B cells [21]. Detailed phenotypic and mole-
cular studies revealed that this memory B-cell subset was 
associated with active disease. In contrast, the entire 
subset of CD27−IgD− B  cells was found to be hetero-
geneous and did not correlate with lupus activity. Th  e 
IgD−CD27− B  cells, but not IgD−CD27−CD95+ memory 
B  cells, were also increased in patients with bacterial 
infections, suggesting that the larger population is 
respon  sive to non-speciﬁ  c immune activation and not 
changes that are unique to SLE. Th  e IgD−CD27−CD95+ 
B-cell subset was a more homogeneous subset within the 
larger IgD−CD27− pool that expressed various activation 
markers (CD86, HLA-DR, and CD38), chemokine recep-
tors (CXCR3, CXCR4, and CXCR5), CD21 (CR2), and 
CD44. Importantly, IgD−CD27−CD95+ B  cells displayed 
higher levels of CD86, CXCR3, HLA-DR, and CD71 
expression and lower levels of CXCR4. Th  ese data are 
consistent with the conclusion that the IgD−CD27−CD95+ 
memory B cells constitute a unique subpopulation that 
appears in increased numbers in SLE and represents 
recently activated memory B  cells resulting from 
intensive GC activity. Th  e expression of CD95 by this 
memory B-cell subset appears to be an important ﬁ  nding 
since it represents a unique characteristic of this 
population of SLE B cells and implies that censoring of 
GC B cells by Fas/Fas-L interaction may be defective in 
this disease.
Regulatory B cells
Th  ough not deﬁ   nitely proven to play an important 
immunoregulatory role in humans, regulatory B  cells 
appear to be induced after antigen-dependent activation 
in mice and, therefore, are also considered to be part of 
the memory subset. In mice, a regulatory 
CD1dhiCD5+CD19hi B-cell subset producing IL-10 was 
shown to control T cell-dependent immune responses 
[27]. Moreover, a speciﬁ  c eﬀ  ect of anti-CD20-mediated 
B-cell depletion on CD4+, but not on CD8+, T-cell 
responses against foreign and self-antigen was demon-
strated [28], implying that IL-10-producing murine 
B cells may play important regulatory roles on pathologic 
T-cell responses. Th  eir precise role in human lupus, 
however, remains to be conﬁ  rmed. A recent report in 
subjects with SLE found a population of regulatory 
CD19+/CD24high/CD38high B  cells [29], a phenotype 
remini  scent of pre-immune B cells. Th   is subset has been 
reported to secrete IL-10 and thereby is able to suppress 
Th  1 and Th  2 functions after CD80/CD86 as well as 
CD40/CD154 ligation. Interestingly, these cells, though 
present in numbers comparable to those of healthy 
controls, lack full functionality in patients with SLE. A 
more recent analysis [30] demonstrated that two 
functionally diﬀ   erent subsets are present within the 
CD24highCD27+ B-cell population: B10 and B10pro, with 
the former ranging between 0.6% and 5% in human 
peripheral blood and able to produce IL-10 within 
5  hours and thereby regulate monocyte function. 
Notably, this study was not able to identify substantial 
diﬀ  erences of B10-cell frequencies between autoimmune 
patients (including those with SLE) and controls. 
Moreover, the relationship between the aforementioned 
human regulatory B-cell and B10 or B10pro is not clear. 
Despite this, the results suggest that some B  cells 
apparently play a key role in controlling T-cell and 
monocyte responses and that an analogous activity may 
be defective in SLE.
Disturbances of plasmablasts/plasma cells in 
systemic lupus erythematosus
One hallmark in adult and juvenile SLE is the signiﬁ  cant 
increase of CD27++ expressing plasmablasts/plasma cells 
in active disease. Th   ese cells are CD19lowCD20−/CD38+++, 
surface Iglow, and express intracellular Ig [14,31,32]. 
Recent studies [33,34] demonstrated that IgA+/β7 integrin+ 
plasmablasts/plasma cells represent steady-state Ig-
secreting cells circulating in the peripheral blood of 
healthy subjects and contrast with antigen- and adjuvant-
stimulated CD62L+/IgG+ plasmablasts/plasma cells 
appear  ing in the blood after purposeful vaccination. Th  e 
steady-state plasmablasts/plasma cells also diﬀ  er  from 
the CD62L−/β7− plasma cells in the bone marrow. Th  e 
bulk of the currently available data indicate that active 
SLE is characterized by increased numbers of circulating 
plasma cells in children as well as adults, indicating 
dysregulation of the homeostasis of these cells [14,31,35]. 
Th  e circu  lating plasmacytosis of active SLE reﬂ  ects the 
ongoing generation of plasma cells/plasmablasts within 
GCs since their appearance was markedly decreased 
when patients with SLE were treated with a monoclonal 
antibody to CD154 that inhibited CD40-CD154 inter-
actions in vivo [36] and that blocked IL-6 as an important 
factor for B-cell diﬀ   erentiation [37] and, there  by, GC 
reactions.
Consistent with this, circulating plasma cells in patients 
with active SLE expressed highly mutated IgVH genes 
with mutations consistent with a GC pattern [38]. 
Notably, the plasma cells were oligoclonal and included 
cells that were actively secreting anti-dsDNA antibodies. 
An expansion of plasma cells in the kidneys of patients 
with lupus nephritis was also observed [39], with these 
cells localizing in close proximity to extrafollicular 
structures. Th  is supports the conclusion that these 
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to the local production of autoantibodies that may be 
pathogenic in this disease.
Models to explain B-cell abnormalities observed in 
the context of systemic lupus erythematosus
It is clear that human lupus is associated with intense 
polyclonal B-cell activation. Abnormalities can be 
observed in pre-immune B-cell populations as well as 
post-GC memory B and plasma cells. Th  e questions of 
how these abnormalities may contribute to lupus patho-
genesis and how this relates to the induction of auto-
antibodies are unresolved, but a number of possibilities 
have been suggested.
1. Systemic lupus erythematosus results from an abnormal 
pre-immune repertoire owing to defective negative 
selection
One mechanism relates to the action of central B-cell 
tolerance checkpoints that ensure that emerging auto-
reactive B  cells are counter-selected [40,41]. In this 
regard, transgenic mice carrying pre-rearranged self-
reactive Ig genes were instrumental in uncovering the 
mechanisms that regulate developing self-reactive B cells. 
However, these models did not allow estimates of the 
frequency at which self-reactive BCRs are generated in 
humans by VH(D)JH recombination with a nearly un-
limited Ig gene repertoire. In humans, an under  standing 
of the potential role of these checkpoints for self-
tolerance is based on the analysis of Ig genes cloned from 
single puriﬁ   ed B  cells at diﬀ   erent stages during their 
development [12,13,42-44]. Th   e results of these analyses 
indicate that autoantigen-binding B  cells       occur fairly 
frequently early in B-cell ontogeny but that these 
autoreactive B  cells are culled at various stages of 
subsequent B-cell ontogeny. In lupus, these checkpoints 
appear to be defective, resulting in the emergence of 
higher numbers of B cells expressing autoreactive BCRs 
than normal. It then follows that there is a greater 
likelihood that either autoantigen-speciﬁ  c activation or 
polyclonal stimulation would have a greater likelihood of 
leading to the production of autoantibodies. Th  is 
likelihood is increased by the fact that peripheral check-
points are also defective in SLE as well as in other 
autoimmune diseases. However, whether these defects in 
peripheral checkpoints contribute to the emergence of 
pathogenic autoimmunity and whether these checkpoint 
abnormalities are primary or secondary to the profound 
abnormalities in B-cell function or cytokine production 
have not been fully delineated.
A number of observations challenge this hypothesis. 
Th  e isolation of certain pre-deﬁ   ned B-cell subsets, 
followed by re-expression of their BCRs, may not reﬂ  ect 
the natural development of these cells that normally 
undergo several rounds of selection before they enter the 
memory B-cell and plasma cell pools. Moreover, it is 
uncertain whether pathogenic autoantibodies emerge as 
a result of the central or peripheral checkpoint abnor-
malities. Pathogenic autoantibodies are encoded largely 
by highly mutated Ig genes and in part by use of certain 
VH genes. Importantly, these pathogenic autoantibodies 
usually lose autoantigen binding when reverted back to 
the germline conﬁ  guration [44-47], implying that they 
did not arise from stimulation of naïve autoreactive 
B cells. It is notable not only that pathogenic auto  anti-
bodies are highly mutated but that studies of the BCR 
repertoire in human SLE demonstrated a diﬀ  usely 
enhanced frequency of somatic hypermutation compared 
with healthy subjects by using single-cell analysis 
[14-16,44].
It is not clear whether germline-encoded polyreactive 
autoantibodies are the precursors of pathogenic autoanti-
bodies. Th  ese polyreactive antibodies are considered to 
be produced by B1 B cells and/or MZ B cells, which are 
under less stringent T-cell control and tend to have long 
CDR3s as exempliﬁ   ed by antibodies during HIV-1 
infection [48], whereas pathogenic autoantibodies have a 
far shorter CDR3. Moreover, the Ig genes of polyreactive 
autoantibodies are usually in germline conﬁ  guration, 
whereas studies of highly mutated pathogenic auto  anti-
bodies indicate that reversion to the germline conﬁ  gura-
tion abolished all autoreactivity, strongly arguing that 
pathogenic autoantibodies did not arise from B  cells 
expressing polyreactive autoantibodies. All of these con-
sidera  tions make it unlikely that pathogenic autoanti-
bodies routinely emerge as a result of defects in check-
points shaping the pre-immune B-cell repertoire.
Th  e association of certain HLA alleles with certain 
autoantibody speciﬁ  cities (that is, anti-Ro/La with HLA-
DR2/3 [49] and a less robust association of HLA-DQw2 
with anti-Smith [50]) suggests that T-cell activation by 
APCs may be essential for these res  ponses and speaks 
against T cell-independent activation of B1 B cells or MZ 
B cells expressing a biased auto  reactive BCR repertoire as 
an important mechanism in the generation of these 
autoantibodies. At least, this appears to be the case for 
autoantibodies to some auto  antigens that may be the 
products of long-lived plasma cells, as deﬁ  ned by their 
resistance to anti-proliferative agents [51]. On the other 
hand, an HLA association with anti-DNA antibodies has 
not been established, suggesting that the short-lived 
plasmablasts producing these auto  antibodies may be less 
dependent on T-cell antigen recognition or alternatively 
that the T-cell epitopes that lead to their production may 
be so promiscuous that an HLA association is not 
apparent. It should be recalled that the HLA region in 
general is the strongest genetic association with lupus in 
genome-wide association studies [52].
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of enhanced germinal center activity and preferential 
selection by autoantigen
An alternative hypothesis postulates that pathogenic 
auto  immunity in SLE arises as a result of increased 
T  cell-dependent GC-like activity that generates auto-
antibodies from B  cells whose BCRs had no intrinsic 
reactivity with autoantigens in germline conﬁ  guration. 
Intrinsic to this hypothesis are the concepts of B-cell 
hyper-responsiveness or exaggerated T-cell responses or 
both, coupled with enhanced somatic hypermutation and 
the accumulation of apoptotic material within GCs with 
the capacity to positively select autoreactive B cells. Th  is 
hypothesis is supported by the ﬁ  ndings that, in murine 
models and human lupus, autoimmunity can arise by 
somatic hypermutation from B-cell precursors with no 
intrinsic autoreactivity.
Th  e importance of T cell-dependent GC reaction in 
SLE is emphasized by the ﬁ  nding of an expansion of post-
GC B-cell subsets in the peripheral blood of patients with 
lupus [14,22,35,44,53]. Although post-GC cells are 
expanded in SLE, little information concerning whether 
this results from the activity of classic or ectopic GCs and 
where these GCs might reside is available. In both classic 
and ectopic GCs, clonal expansion of B cells along with 
somatic hypermutation of Ig gene rearrangements and Ig 
heavy-chain class-switch recombination are induced. 
Resulting memory B cells can be positively selected by 
immune complexes residing on the surface of follicular 
dendritic cells (FDCs) and negatively selected by the 
presence of soluble autoantigen. Although there are 
minimal data, it is possible that the stringency of negative 
selection might be less in ectopic GCs. Th   e three diﬀ  erent 
stages of GC formation and activity, including (a) 
establishment of GC structures, (b) the activity of these 
sites of generation of B-cell eﬀ  ectors, and the (c) selection 
of high-avidity eﬀ  ector cells by FDCs, evolve over time 
after antigen stimulation.
2a. Generation of germinal centers
Given the enhanced GC activity and increased formation 
of ectopic GCs known to result in the generation of 
antigen-experienced memory B and plasma cells, there is 
a possibility that factors involved in establishing GC 
structures, including T follicular helper (TFH) cells, IL-21, 
IL-6, CXCL13, TNFβ, and inducible T-cell co-stimulator 
(ICOS), play a critical role in SLE. In this regard, the 
sanroque mouse that harbors a mutation that regulates 
ICOS expression on T cells develops a very aggressive 
form of lupus. In this context, CD154/CD40 and ICOS-
L/ICOS [54] as well as CD80/CD86 [55] ligation have 
been suggested to be necessary for the activation of 
B cells but also indispensable for the activation of auto-
reactive T cells [56] and the induction of regulatory 
B cells [29]. With regard to the important involvement of 
co-stimulatory ligands expressed on plasma cells and 
memory B cells in SLE, it has been shown that T and 
B  cells from SLE blood spontaneously express CD154 
[36], suggesting a potential abnormal release of activated 
lymphocytes from the GCs or insuﬃ   cient  selection 
permitting abnormal egress of memory B cells into the 
blood. Similarly, CD4+ and CD8+ T cells from patients 
with lupus were identiﬁ   ed to have enhanced ICOS 
expres  sion, whereas memory B cells substantially down-
regulate ICOS-L presumably as a result of recent T-cell 
instruction [39].
Th   e type I cytokine, IL-21, essential for co-stimulated 
B  cells to diﬀ  erentiate into plasma cells [20], has also 
been suggested to be involved in SLE pathogenesis. Th  is 
hypothesis is supported by data from IL-21R−/− mice with 
diminished IgG1 and IgG2b in response to immunization 
and those from IL-21 transgenic mice that develop 
hyper  gammaglobulinemia [57]. Moreover, signiﬁ  cantly 
enhanced IL-21 was found in the BXSB-Yaa+ and the 
sanroque murine models of SLE [57]. In addition, block-
ing of IL-21 activity was employed successfully in the 
MRL lupus mouse consistently with observations in 
BXSB-Yaa+ mice crossed with the IL-21R−/− mouse in 
which all manifestations of SLE disappeared [20,58]. 
IL-21 is constitutively produced by CXCR5+ T FH cells, a 
subpopulation of T cells that reside in B-cell follicles and 
are specialized to provide initial help to antigen-activated 
B cells [59]. In addition, TFH cells require ICOS stimu-
lation for their generation, and their diﬀ  erentiation  is 
regulated by the transcriptional repressor, bcl-6 [60]. 
Notably, the sanroque mouse that constitutively over-
expresses ICOS contains an expanded population of TFH 
cells that produce large amounts of IL-21 inducing the 
lupus phenotype. Th  ese  ﬁ  ndings of the linkage between 
ICOS and IL-21 required for B-cell stimulation in 
secondary lymphoid organs represent further critical 
evidence that factors involved in GC induction or 
maintenance or both are of critical importance in human 
SLE. Th   e role for GCs in SLE is further supported by data 
showing that polymorphisms of both IL-21 and the 
IL-21R are associated with SLE [61]. In this context, a 
direct eﬀ  ect of interferon-alpha on B cells is less likely, 
but type I interferon [62] can also induce BAFF/BLyS by 
myeloid cells, subsequently enhancing autoreactive B-cell 
survival [63]. Overall, a complex set of ligands and cyto-
kines appear to be important to initiate GC structure 
functionally and deﬁ  ne their anatomic site.
Enhanced availability of GC factors involved in the 
establishment of GCs in SLE may explain the formation 
of so-called ectopic GCs considered to be involved in the 
diﬀ  erentiation of B  cells and plasma cells under auto-
immune conditions. Although conclusive evidence con-
cern  ing whether ectopic GCs are speciﬁ  c  for 
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occurrence during infectious diseases such as viral 
rhinitis suggests that they are not unique to autoimmune 
conditions but still may contribute. Moreover, it is not 
clear that lupus ectopic GCs are uniquely defective in 
negative selection since even classic GCs in tonsils from 
patients with SLE were found to be defective in selection 
against 9G4-expressing B cells.
Ectopic GC structures may be involved in T cell-inde-
pendent activation of memory B cells by co-engagement 
of the BCR with activating receptors for BAFF and APRIL 
(TACI, TNFRSF13B) or ligation of TLR9 by bacterial 
DNA or TLR-7 or TLR-8 by single-stranded RNA, result-
ing in activation of B  cells by an NF-κB-dependent 
mecha  nism. Signaling via TLRs, in particular TLR9 
induced by dsDNA and TLR7 by single-stranded DNA/
RNA, uniquely stimulates MyD88-dependent memory 
B cells [64] and may contribute to plasmacytosis in SLE.
It needs to be emphasized that other cells may also be 
involved in the initiation of B-cell activation in auto-
immune disease. In this context, a recent study [65] using 
conditional knockout mice for DCs on an MRL.Faslpr 
background found that induction of plasmablasts and 
autoantibodies were dependent on DCs possibly related 
to a role in T cell-independent extrafollicular responses.   
Total Ig levels remained stable in these animals. 
Interestingly, this study highlights that there may be 
diﬀ  erences in the contributions of interactions between 
DCs and T cells versus DCs and B cells in certain auto-
immune diseases.
2b. Antigen-presenting cell function
B cells can act as professional APCs. Th   is conclusion was 
suggested by data from animal models [66] in which a 
lupus-like disease, albeit mild, developed when 
autoimmune-prone mice were reconstituted with B cells 
that lacked the ability to secrete Ig, whereas no disease 
was seen in the complete absence of B cells. Th  us, an 
important function of memory B cells may be antigen 
presentation, which is facilitated by the expression of 
high-avidity BCR and also major histocompatibility 
complex (MHC) class II and co-stimulatory molecules, 
and, as a result, memory B cells are likely to be able to 
activate and expand memory T cells.
2c. T cell-independent activation of memory B cells
In addition to having a potential role as APCs, abundant 
memory B-cell subsets in SLE with their characteristic 
hyper-responsiveness to various stimuli, such as TLR 
ligands, IL-21, BAFF, IL-10, BCR activation, and co-
stimu  latory ligand-ligand interactions, can result in an 
increase of Ig-producing plasma cells without strong selec-
tion criteria as required for naïve B cells. Th   is increase in 
the reactivity of memory B  cells could also reﬂ  ect the 
increased production of cytokines characteristic of SLE, 
such as IL-6, lymphotoxin-beta, IL-4, IL-10, and IL-21. In 
a substantial number of patients with SLE, interferon-
alpha produced by tissue-resident plasmacytoid DCs that 
are reduced in the blood of patients with SLE may 
ultimately induce the increased B-cell hyperactivity by 
inducing the production of BAFF/BLyS (TNFSF13b) [67].
2d. Somatic hypermutation and autoimmunity
A number of studies provided evidence that somatic 
hypermutation was required for the generation of 
disease-associated anti-nuclear antibodies (ANAs). A 
recent instructive study [47] using TdT−/− mice and 
therefore avoiding CDR3 autoreactive binding introduced 
by junctional diversity showed that spontaneous auto-
immunity was closely related to high-avidity autoimmune 
B  cells created from non-autoreactive precursors by 
somatic hypermutation. Th  e mutational process intro-
duced encoding codons as a result of targeted mutations 
toward mutational hot spots (AGC and AGT/serine 
codons). Consistent with earlier studies suggesting the 
importance of arginine residues in anti-nuclear activity, 
this information supports the conclusion that somatic 
hypermutation is importantly involved in inducing ANA-
speciﬁ  c B cells in a T cell-dependent manner. Only 1 out 
of 10 clones (J7.13 using a Jk1 gene segment) retained 
ANA-binding activity after reversion to germline 
sequences consistent with the possibility that it either 
escaped all tolerance checkpoints in B-cell development 
or may have defects in receptor editing. Th   e data indicate 
that the majority of autoreactive B cells emerge as a result 
of somatic hypermutation, although a minority of auto-
antigen-binding B cells can manage to escape tolerance 
consistent with the contention that some autoimmunity 
may arise from checkpoint abnormalities permitting an 
expanded autoimmune repertoire in the pre-immune 
B-cell compartment. As mentioned above, the impor-
tance of somatic hypermutation in the development of 
autoimmunity has been demonstrated for autoreactive 
monoclonal antibodies that were derived from lupus 
patients and that lost autoantigen binding when back-
mutated to the germline conﬁ   guration [44,45]. Th  ese 
independent data obtained by diﬀ  erent  technologies 
indicate that somatic hypermutation is an almost 
universal factor establishing autoreactivity in SLE.
Additional results also have focused on the role of 
somatic hypermutation in the generation of autoanti-
bodies. Plasma cells from subjects with active SLE 
manifest extensively mutated VH and VL genes, and the 
pattern of mutation is comparable to that noted following 
T cell-dependent antigen stimulation [14-17,44-46,68] 
(Figure 2). Th  e Ig gene rearrangements of such plasma 
cells show an increased replacement-to-silent (R/S) muta-
tion ratio within complementarity-determining regions 
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(FRs) as well as exhibiting mutational targeting into 
RGYW/  WRCY mutation hot spots. Th   e available data are 
all consistent with a GC-type molecular mutation pattern.
A comparison of the molecular characteristics of VH 
gene rearrangements of antigen-experienced B cells from 
healthy subjects and those circulating in SLE patients 
(Figure 3) shows that one diﬀ  erence is a higher R/S ratio 
within CDRs versus FRs in SLE compared with healthy 
volunteers (Figure 3b) undergoing tetanus booster vacci-
nation. In recent years, mutations targeted especially to 
the Gs and Cs of RGYW/WRCY motifs have become of 
special interest since they are thought to be the direct 
conse  quence of AIDCA deamination [69] occurring 
typically within GCs, as this pattern is speciﬁ  cally 
reduced in CD154-deﬁ  cient individuals, virtually lacking 
Figure 2. Potential pathways involved in autoantibody 
generation in systemic lupus erythematosus (SLE). SHM, somatic 
hypermutation.
Figure 3. Comparative analysis of molecular germinal center signatures between antigen-experienced cells obtained from vaccinated 
controls versus systemic lupus erythematosus (SLE). VH sequences of individual cells sorted as recombinant C-fragment of tetanus toxin 
(TT)-specifi  c plasma cells (TT+ PCs) and TT-specifi  c memory B cells (TT+ mBCs) were pooled from three healthy donors after tetanus booster [82] 
and plasma cells from one patient with SLE (SLE PCs) [14]. TT+ PCs and TT+ mBCs serve as eff  ector cells generated as a result of prototypic T cell-
dependent responses. (a) Mutation frequency. Each dot represents the value for one individual cell. (b) Ratios of replacement (R) to silent (S) 
mutations within complementarity-determining regions (CDRs) 1 and 2 and framework regions (FRs), respectively. (c) Frequency of mutations 
located within the two motifs RGYW and WRCY (R = purine, Y = pyrimidine, and W = adenine/thymine). (d) CDR3 length of individual B cells related 
to the underlying total number of mutations per sequence. Sequences of each cell type were divided into three categories according to their VH 
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somatic hypermutations and the length of CDR3, both of 
which are considered to be markers of the inﬂ  uence of 
antigen, were comparable between healthy subjects and 
subjects with SLE (Figure 3a,c,d). Th  us, the higher R/S 
ratio in CDRs in patients with SLE suggests that defects 
of selection after the GC reaction likely play a major role 
in SLE. Possibly, the negative selection within GCs could 
be overridden or exhausted by the greatly increased 
immune activity in GCs so that the emergence of auto-
reactive B cells is permitted.
2e. Selection
A variety of results in human and murine SLE are 
consistent with the possibility that selection is critically 
impaired in censoring autoreactive B  cells after GC 
reactions. One possibility to consider is that an abnor-
mality in selection may relate to defects in apoptosis 
characteristic of SLE. In this regard, deﬁ  ciencies in the 
clearance of apoptotic material in SLE [41,71] appear to 
play an important role. Herrmann and colleagues [72] 
demonstrated in vitro that phagocytes in about 50% of 
patients with SLE show reduced phagocytotic activity of 
autologous apoptotic material. With regard to GCs in 
vivo, tingible body macrophages, which are phagocytes 
that most eﬃ   ciently engulf apoptotic cells and locate in 
close proximity to FDCs, were reduced in total numbers 
in a subgroup of patients with SLE. Furthermore, those 
tingible body macrophages rarely contained apoptotic 
material but instead apoptotic debris was found to be 
uningested outside these phagocytes [73]. Consequently, 
DCs may present self-antigens via MHC molecules on 
their surfaces [74] and may lead to activation of auto-
reactive T cells. Moreover, apoptotic material has been 
visualized on the surface of FDC within GCs [75], 
suggest  ing that they may be capable of acting to positively 
select autoreactive memory B  cells that emerge from 
GCs. Evidence that these ‘censoring units’ are apparently 
abnormal and may positively select autoreactive B cells 
comes from a study showing that B cells expressing the 
anti-DNA encoding 9G4 idiotype were detectable in 
tonsils of patients with SLE but are not found in normal 
GCs [26]. Th   ese data support the view that malfunction 
of the clearance of apoptotic material may not only 
induce but also select autoreactive B cells in GCs. Th  us, 
there is a possibility that autoantigens derived from 
ineﬃ   cient clearance of apoptotic remnants and presented 
by FDCs are of central importance in the selection of 
autoantibodies (Figure 4).
Clinical  a       spects  of  therapeutic  strategies  targeting 
B cells
Instructive data have been obtained from a number of 
recent clinical trials of targeted B-cell therapy. 
Immuno  therapies using the chimeric anti-CD20 antibody 
rituxi  mab [9], tocilizumab blocking IL-6 eﬀ  ects  [37], 
blocking CD154-CD40 interactions [36], and autologous 
stem cell transplantation [18] in severe SLE demonstrated 
that the expanded memory B-cell and plasma cell 
populations could be normalized and resulted in 
predominantly naïve B cells after successful interventions. 
In contrast, the BAFF/BLyS neutralizing antibody, 
belimumab, caused a decrease in naïve B cells and plasma 
cells but an increase in circulating memory B cells [76]. 
Despite changes in B-cell phenotype, two trials 
investigating rituximab in SLE did not meet their clinical 
endpoints [77], whereas two trials of belimumab showed 
signiﬁ  cant clinical bene  ﬁ  t. Th   e disparate results of these 
trials raise questions about the pharmacodynamic 
diﬀ   erences of these reagents and their most relevant 
eﬀ   ects. While no data on lymphocyte subsets are 
available from trials studying abata  cept in SLE [78], 
blockade of co-stimulation between CD154/CD40 in an 
early study and blockade of ICOS/ICOS-L in preclinical 
studies [39] are consistent with the idea that inhibition of 
certain GC processes are prime candidates for successful 
interventions.
Interestingly, blocking BAFF/BLys by the humanized 
monoclonal belimumab has been reported to prefer  en-
tially reduce transitional naïve B cells and plasma cells 
[76], indicating a possible involvement of this cytokine in 
early and late B-cell diﬀ  erentiation. Another monoclonal 
antibody directed against CD22 expressed on B  cells, 
epratuzumab, was shown to preferentially reduce peri-
pheral CD27− B cells [79]. A recent observation of higher 
expression of CD22 on CD27− naïve versus CD27+ memory 
B  cells may provide an explanation for this disparity. 
Moreover, enhanced binding of epratuzumab to naïve 
Figure 4. Characteristics of somatic hypermutation and 
generation of autoantibodies. AID, activation-induced cytidine 
deaminase; CDR, complementarity-determining region; Ig, 
immuonglobulin; RGYW, purine (R), guanine (G), pyrimidine (Y), 
adenine/thymine (W); SR, silent-to-replacement; SHM, somatic 
hypermutation; WRCY, adenine/thymine (W), purine (R), cytosine (C), 
pyrimidine (Y).
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toward CXCL12 in vitro along with reduced expression 
of CD62L and β7 integrin [80]. Th  ese two possibilities 
imply that B cells are involved in SLE, although it remains 
to be shown whether they interfere directly or indirectly 
with GC activation versus positive selection on FDCs.
Conclusions
Although the underlying causes of B-cell over-reactivity 
in SLE remain to be fully delineated, the data indicate 
that this increased activity contributes to the emergence 
of autoimmunity. Two major abnormalities of B cells in 
lupus are defective central checkpoints with a resultant 
partially autoreactive pre-immune repertoire, on the one 
hand, and enhanced T cell-dependent B-cell activation in 
the periphery with autoimmunity arising from somatic 
hypermutation and selected by apoptotic material dis-
played on FDC on the other. Although both may 
contribute to the emergence of autoimmunity, most of 
the data favor the latter as a major cause of the develop-
ment of pathogenic autoantibodies. As such, this hypo-
the  sis would indicate that a substantial part of autoimmu-
nity is not strictly initiated by autoantigen stimulating a 
speciﬁ  c response directed to the initiating self-antigen 
but rather by autoantigen selecting B cells for survival 
that have acquired autoreactivity by somatic hypermuta-
tion. Moreover, the results indicate that therapies aimed 
at decreasing B-cell reactivity during T cell-dependent 
immune response in GCs may have a positive role in 
treating subjects with SLE.
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